GEMoaB Monoclonals
| Company type | GmbH |
|---|---|
| Industry | Biotechnology Pharmaceutical |
| Founded | 2011 |
| Founder | Gerhard Ehninger, Michael Bachmann |
| Headquarters | Dresden, Germany |
Key people | Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger (CMO)[1] |
| Products | GEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA |
| Revenue | n.a. |
| Website | www |
GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.[2] [3] It was acquired by the new company AvenCell Therapeutics in 2021.[4][5]
Company background
[edit]To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.[6]
Scientific and strategic board
[edit]The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).[7]
Co-operations
[edit]Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.[8]
Drugs currently under development
[edit]- GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML[9][10]
- GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours[11]
- UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
- UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours
Literatur
[edit]- Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141. doi:10.1038/s41598-020-59082-4, PMID 32034289.
- Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. doi:10.1182/blood-2018-99-113288.
- Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. doi:10.1080/2162402X.2019.1659095, PMID 31646084.
- C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967, doi:10.1038/leu.2013.18, PMID 23325142.
See also
[edit]References
[edit]- ^ Leadership Team Leadership Team, Company Website, Retrieved: July 15, 2021
- ^ Get to know GEMoaB, Company Website, Retrieved: May 11, 2020
- ^ "GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias". chemie-link.de. 9 March 2020. Retrieved 11 May 2020.
- ^ "Clinical-stage biopharma company targets hard-to-treat cancers". AvenCell. Retrieved 12 February 2024.
- ^ "Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company". Blackstone. 22 June 2021. Retrieved 12 February 2024.
- ^ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S. e458, doi:10.1038/bcj.2016.61, PMID 27518241, PMC 5022178.
- ^ Scientific and Strategic Advisory Board[permanent dead link], Company Website, Retrieved: May 11, 2020
- ^ Our Partners, Company Website, Retrieved: May 11, 2020
- ^ AML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020
- ^ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020
- ^ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020